Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Frank A. Sinicrope, et al.
2025年5月30日～6月3日に米国シカゴとオンラインのハイブリッドで開催される、米国臨床腫瘍学会年次集会（2025 Annual Meeting of the American Society of Clinical Oncology®）より、大腸癌、胃癌、膵癌などの消化器癌の注目演題のレポートをお届けします。臨床研究の第一線で活躍するドクターにより執筆、監修されたレポートを楽しみにしてください。
更新履歴
演題レポート
Colorectal Cancer
Plenary Abstract #LBA1
大腸癌
Oral Abstract #LBA3500
大腸癌
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses
Elena Elez, et al.
Oral Abstract #3501
大腸癌
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analysis from CheckMate 8HW
Heinz-Josef Lenz, et al.
Oral Abstract #3503
大腸癌
ctDNA-guided Adjuvant Chemotherapy Escalation in stage III Colon Cancer: Primary Analysis of the ctDNA-Positive Cohort from the Randomized AGITG DYNAMIC-III Trial (Intergroup Study of AGITG and CCTG)
Jeanne Tie, et al.
Oral Abstract #3505
大腸癌
Perioperative systemic therapy for resectable colorectal peritoneal metastases: a multicenter randomized phase 3 trial (CAIRO6)
Ignace De Hingh, et al.
Oral Abstract #3506
大腸癌
Long-term safety and efficacy of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer: CodeBreaK 101 (phase 1b)
John H. Strickler, et al.
Oral Abstract #3512
大腸癌
Upfront modified FOLFOXIRI plus panitumumab(pan) versus FLFOX/pan for unresectable RAS and BRAF wild-type mCRC: overall survival results from the phase III TRIPLETE study by GONO
Veronica Conca, et al.
Non-Colorectal Cancer
Plenary Abstract #LBA5
胃癌
食道胃接合部癌
Event-free survival (EFS) in MATTERHORN: a Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
Yelena Y. Janjigian, et al.
Oral Abstract #LBA4002
胃癌
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study
Kohei Shitara, et al.
Oral Abstract #4003
胃癌
食道胃接合部癌
Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary Results from a randomized, open-label, phase II trial (CT041-ST-01)
Changsong Qi, et al.
Oral Abstract #LBA4004
膵癌
Results of a randomized phase 3 trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma: CASSANDRA – PACT-21 trial
Michele Reni, et al.
Oral Abstract #LBA4005
膵癌
PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC)
Vincent Picozzi, et al.